Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7636)	11/4/1998 11:14:00 AM
From: Bluegreen	Read Replies (2) \| Respond to of 17367

Does anybody know the number per year of spinal taps done just in the US for detection of infections? If clinicians do this invasive procedure in this setting, what is on their list of probable diagnosis? Now once again what trial is ending soon? What will be the indication for Neuprex usage if approved? Do you have plenty of time to wait for spinal tap results before starting treatment? Is Neuprex a relative safe product? Does it make a difference time wise when you give Neuprex when you have certain types of infections on your list of probable diagnosis? Are these questions clinicians have to face around the world everyday? Now explain to me how this indication for Neuprex if approved will be a "niche" market. Since situation is serious enough for the clinician to do a spinal tap, in my opinion cost of Neuprex would not be at issue.

To: Bluegreen who wrote (7636)	11/4/1998 7:14:00 PM
From: Robert S.	Read Replies (1) \| Respond to of 17367

I must say, it takes real chutzpah to make a statement like this Which brings me to the thought that time is short in hearing from the DSMB. Funny George how some are engrossed in sepsis* debate... after recently pronouncing the following To: StockDoc (6930 ) From: Bluegreen Wednesday, Aug 12 1998 6:41PM ET Reply # of 7642 Doc, Doc, Doc, Sepsis is like Cancer???? I liked how you slipped in gram positive example at this stage of the game. If you are serious about Xoma, how about doing some research on BPI especially rBPI21. You might want to check research also on BPI in regards to gram neg. sepsis. Let us concentrate on GRAM NEG. SEPTICEMIA* and also synergy with antibiotics first THEN let us deal with gram positive events shall we? What else at this stage? Well why don't you look at phase II results on Hemo. Trauma trial. Might you turn ARDS into a niche group also?